News & Updates
Filter by Specialty:
Olanzapine a favourable alternative to dexamethasone for CINV
Olanzapine administered at a dose of 5 mg was noninferior to dexamethasone and is associated with fewer adverse effects than dexamethasone for chemotherapy-induced nausea and vomiting (CINV), according to data presented at ESMO 2021.
Olanzapine a favourable alternative to dexamethasone for CINV
27 Sep 2021
Ribociclib plus letrozole improves OS in hormone receptor–positive, HER2-negative advanced breast cancer
A combined regimen of ribociclib plus letrozole as first-line treatment provides a statistically significant and clinically meaningful overall survival (OS) benefit vs placebo plus letrozole in postmenopausal patients with hormone receptor–positive and HER2-negative advanced breast cancer (BC), results of the phase III MONALEESA-2 study have shown.
Ribociclib plus letrozole improves OS in hormone receptor–positive, HER2-negative advanced breast cancer
27 Sep 2021
T-Dxd improves PFS vs T-DM1 in second-line HER2-positive mBC treatment
Trastuzumab deruxtecan (T-Dxd) provides a highly clinically meaningful and statistically significant improvement in progression-free survival (PFS) vs trastuzumab emtansine (T-DM1) in second-line treatment of HER2-positive metastatic breast cancer (mBC), results of the phase III DESTINY-Breast03 trial have shown.